Genetic Polymorphisms of Pharmacogenomic VIP Variants in the Hui Population from Ningxia Province of China

Overview

Journal Funct Integr Genomics

Publisher Springer

Specialties Genetics
Molecular Biology

Date 2023 Mar 17

PMID 36930384

Authors

Wenqian Zhou

Jinping Guo

Yujie Li

Xiaoya Ma

Shuangyu Yang

Jie Wei

Huan Zhang

Shanshan Zhang

Tianbo Jin

Affiliations

Soon will be listed here.

Abstract

Pharmacogenomics has been widely used to study the very important pharmacogenetic (VIP) variants among different populations. However, there is little pharmacogenomic information about the Chinese Hui population. Our research aimed to reveal the outstandingly different loci in the Hui population, and provide a theoretical foundation for personalized drug use in the Hui population, so as to facilitate more effective treatment of diseases. This study genotyped 53 VIP variants of 26 genes in 200 independent Hui individuals based on the Pharmacogenetics and Pharmacogenomics Knowledge Base (PharmGKB). Remarkable differences in the genotype and allele frequencies between the Hui and 26 other populations from the 1000 Genomes Project were assessed using the χ test. The genotype and allele frequencies of single nucleotide polymorphisms (SNPs) in PTGS2 (rs20417), NAT2 (rs1801280), NAT2 (rs1208), ACE (rs4291), and CYP2D6 (rs1065852) were considerably different in the Hui population compared with those in the other 26 populations. Besides, using the PharmGKB database, we identified several VIP variants that may alter the drug metabolism of ibuprofen, rofecoxib (PTGS2), captopril (ACE), citalopram, and escitalopram (CYP2D6). We also discovered other variants associated with adverse reactions to cisplatin and cyclophosphamide (NAT2). Our study indicated that the loci of PTGS2 (rs20417), NAT2 (rs1801280 and rs1208), ACE (rs4291), and CYP2D6 (rs1065852) in the Hui population were obviously different from those in the other 26 populations, which provides reliable information for predicting drug efficacy. Besides, it supplements the pharmacogenomic knowledge of the Hui population and lays the foundation for the individualized treatment for the Hui population.

References

Adole P, Kharbanda P, Sharma S . N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - A pilot study. Indian J Med Res. 2016; 143(5):581-90. PMC: 4989831. DOI: 10.4103/0971-5916.187106. View

Alwi Z . The Use of SNPs in Pharmacogenomics Studies. Malays J Med Sci. 2012; 12(2):4-12. PMC: 3349395. View

Barbarino J, Whirl-Carrillo M, Altman R, Klein T . PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018; 10(4):e1417. PMC: 6002921. DOI: 10.1002/wsbm.1417. View

Cacabelos R, Cacabelos N, Carril J . The role of pharmacogenomics in adverse drug reactions. Expert Rev Clin Pharmacol. 2019; 12(5):407-442. DOI: 10.1080/17512433.2019.1597706. View

Capone M, Tacconelli S, Di Francesco L, Sacchetti A, Sciulli M, Patrignani P . Pharmacodynamic of cyclooxygenase inhibitors in humans. Prostaglandins Other Lipid Mediat. 2006; 82(1-4):85-94. DOI: 10.1016/j.prostaglandins.2006.05.019. View

de Oliveira F, Bertolucci P, Chen E, Smith M . Brain-penetrating angiotensin-converting enzyme inhibitors and cognitive change in patients with dementia due to Alzheimer's disease. J Alzheimers Dis. 2014; 42 Suppl 3:S321-4. DOI: 10.3233/JAD-132189. View

Ding Y, He P, He N, Li Q, Sun J, Yao J . Genetic polymorphisms of pharmacogenomic VIP variants in Li nationality of southern China. Environ Toxicol Pharmacol. 2016; 42:237-42. DOI: 10.1016/j.etap.2016.02.003. View

de Oliveira F, Berretta J, Chen E, Smith M, Bertolucci P . Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease. Colomb Med (Cali). 2016; 47(2):76-80. PMC: 4975126. View

Fukino K, Sasaki Y, Hirai S, Nakamura T, Hashimoto M, Yamagishi F . Effects of N-acetyltransferase 2 (NAT2), CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of isoniazid and metabolites in tuberculosis patients. J Toxicol Sci. 2008; 33(2):187-95. DOI: 10.2131/jts.33.187. View

10.

Hadjadj S, Tarnow L, Forsblom C, Kazeem G, Marre M, Groop P . Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations. J Am Soc Nephrol. 2007; 18(4):1284-91. DOI: 10.1681/ASN.2006101102. View

11.

Hailu A, Mohammed S . Adverse Drug Reaction Reporting in Ethiopia: Systematic Review. Biomed Res Int. 2020; 2020:8569314. PMC: 7439161. DOI: 10.1155/2020/8569314. View

12.

Hein D . N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin Drug Metab Toxicol. 2009; 5(4):353-66. PMC: 2762189. DOI: 10.1517/17425250902877698. View

13.

Ingelman-Sundberg M, Sim S, Gomez A, Rodriguez-Antona C . Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther. 2007; 116(3):496-526. DOI: 10.1016/j.pharmthera.2007.09.004. View

14.

Ji Y, Schaid D, Desta Z, Kubo M, Batzler A, Snyder K . Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations. Br J Clin Pharmacol. 2014; 78(2):373-83. PMC: 4137829. DOI: 10.1111/bcp.12348. View

15.

Johnson A, Gong Y, Wang D, Langaee T, Shin J, Cooper-DeHoff R . Promoter polymorphisms in ACE (angiotensin I-converting enzyme) associated with clinical outcomes in hypertension. Clin Pharmacol Ther. 2008; 85(1):36-44. PMC: 2709290. DOI: 10.1038/clpt.2008.194. View

16.

Kagaya H, Miura M, Niioka T, Saito M, Numakura K, Habuchi T . Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients. Antimicrob Agents Chemother. 2011; 56(2):825-9. PMC: 3264276. DOI: 10.1128/AAC.05037-11. View

17.

Katara P . Single nucleotide polymorphism and its dynamics for pharmacogenomics. Interdiscip Sci. 2014; 6(2):85-92. DOI: 10.1007/s12539-013-0007-x. View

18.

Khrunin A, Khokhrin D, Moisseev A, Gorbunova V, Limborska S . Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer. Pharmacogenomics. 2014; 15(3):329-37. DOI: 10.2217/pgs.13.237. View

19.

Kim T, Chang H, Park S, Nam B, Park J, Rhim T . Association of angiotensin I-converting enzyme gene polymorphisms with aspirin intolerance in asthmatics. Clin Exp Allergy. 2008; 38(11):1727-37. DOI: 10.1111/j.1365-2222.2008.03082.x. View

20.

Kobayashi K, Chiba K, Yagi T, Shimada N, Taniguchi T, Horie T . Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther. 1997; 280(2):927-33. View